There is no single correct number, and the published range is enormous: six, seven, around a hundred, more than a hundred and thirty. Every one of those can be defended. They differ because "peptide" and "approved" are each doing more work than they look like they are.
Here is what each figure actually counts.
Around 100 to 130 — every peptide drug the FDA has ever approved
The largest and most commonly cited range. It counts therapeutic peptides approved as prescription drugs since insulin reached patients in 1922: insulins, GLP-1 agonists, oxytocin, ACTH analogues, GnRH analogues and dozens more. Published counts cluster around 100, and reach 130 by including recent approvals and counting formulations separately.
The spread inside that range is ordinary bookkeeping — whether a molecule is counted once or once per approved product, whether withdrawn drugs stay on the list, and where the line falls between a peptide and a small protein. Nobody is wrong. They are using different rules and mostly not stating them.
If the question is whether peptides are a real class of medicine, this is the number that answers it, and the answer is emphatically yes.
7 — the compounds we track with an approved product
This is our figure and the narrowest on the page. We track 42 compounds marketed directly to consumers, and 7 of them have an FDA-approved product:
- Afamelanotide — FDA-approved (Scenesse, 2019) to increase pain-free light exposure in adults with erythropoietic protoporphyria. Not approved for tanning.
- Elamipretide — FDA-approved (Forzinity, accelerated approval) to improve muscle strength in Barth syndrome, an ultra-rare mitochondrial disease. Approval does not extend to general anti-aging use.
- Liraglutide — FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications.
- PT-141 — FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Grey-market "PT-141" is not the approved product.
- Semaglutide — FDA-approved for type 2 diabetes and chronic weight management.
- Tesamorelin — FDA-approved for HIV-associated lipodystrophy.
- Tirzepatide — FDA-approved for type 2 diabetes and chronic weight management.
That is not a count of peptide drugs. It is a count of the consumer peptide market that happens to overlap with approved medicine. Most of the hundred-plus approved peptide drugs are hospital and specialist medicines nobody sells in a vial online, so they fall outside what this site tracks.
The distinction that matters most here: approval is for a specific use, in a specific population, as a specific product. Tesamorelin is approved for HIV-associated lipodystrophy, not general fat loss. Bremelanotide is approved as Vyleesi for one condition in premenopausal women — what is sold online as "PT-141" is not that product. An approved molecule is not an approved use.
Six — the peptides an FDA advisory committee voted on in July 2026
This number appears throughout recent coverage and is the one most often misread. It refers to substances a committee considered for pharmacy compounding eligibility, not for approval. A vote is not an approval, an advisory committee does not approve drugs, and the vote is not binding. We wrote that up separately: what the July 2026 vote actually means.
Eleven — approved peptides that can be taken as a pill
Occasionally quoted as though it were the total. Of roughly 100 approved peptide drugs, only about 11 are orally administered. Peptides are large molecules and are usually destroyed in the gut, which is why most are injected. Oral semaglutide was the first oral GLP-1.
Which number should you use?
Whichever matches your question, stated out loud:
- Is this class of drug legitimate? Around 100. Peptides are ordinary, well-established medicine.
- Is the specific thing I am about to buy approved? Almost certainly not — you can check a compound or a stack.
- Was it approved for what it is sold for? A different question again, and the one that catches people out. Approval for one condition is not approval for everything.
None of this is a statement about whether any peptide works. Approval status is a regulatory fact, not a measure of evidence, and an unapproved compound has not thereby been shown to fail.